COPENHAGEN, Nov 2 (Reuters) - Bavarian Nordic has received a four-year contract from the British government for its vaccine ...

MVA-BN is indicated for use in individuals from the age of two years considered at smallpox or mpox infection risk.

Emergent BioSolutions is set to release fourth-quarter results—and further discuss its vaccine sale to Bavarian Nordic—on a conference call set for Feb. 27. (Photo by SAUL LOEB/AFP via Getty Images) ...

Bavarian Nordic (CPSE:BAVA) raised its full-year 2026 guidance following stronger Travel Health activity, with increased ...

COPENHAGEN, Denmark, November 2, 2026 – (OMX: BAVA) today announced that it has been awarded a new multi-year contract by ...

Bavarian Nordic donates 75,000 doses of MVA-BN ® and will also supply 150,000 doses to new global mpox vaccine emergency stockpile. Building emergency reserves is an important milestone in global mpox ...

Bavarian Nordic will also supply an additional $3 million worth of liquid frozen doses of its smallpox/mpox vaccine in 2023. (Bavarian Nordic) After coming to the rescue during the mpox outbreak in ...

Bavarian Nordic (OTCPK:BVNKF) (BAVN) Monday said it agreed to a 19 billion Danish kroner ($2.99 billion) takeover from private-equity companies Permira and Nordic Capital. Under the deal, accepting ...

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and ...

Bavarian Nordic A/S (BAVA.CO, BVNRY), on Monday announced that it has been awarded a four-year vaccine supply contract by the UK Government through the UK Health Security Agency. Under the contract, ...

Bavarian Nordic A/S, a prominent Danish biotechnology company specializing in vaccine development, has accepted a takeover offer valued at DKK 19 billion (approximately $2.99 billion) from a ...

The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox ...